Loading…
← CockpitCompetitor Analysis › ALEMBICLTD.NS Alembic LimitedOpen in the cockpit ↗

Alembic LimitedALEMBICLTD.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum leader 90
Mkt cap
$309M
US dollars, full cap
Free float
28%
of shares outstanding
$/day
$3.19M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-16.5 pp
WACC 18.1%
Hurdle
+18 pp
Req g minus delivered
Close · INR₹112.41
1D-1.2%
1W-2.8%
1M+18.1%
3M+25.1%
6M+25.1%
YTD+11.1%
1Y+12.7%
ATR %4.6%
Beta1.34
52w lowhigh4.9% off high

What Alembic does

Employees: 329

Alembic at a glance

Size Alembic (ALEMBICLTD.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $309M, the 1054th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹112.41 on 18 Nov 2026.

Performance Over six months the shares gained 25.1%, against -22.8% for the median peer and +3.8% for the India market (cap-weighted) — 4th highest of 21 in its peer set.

Growth Revenue fell 4.7% over the last twelve months (peer median +2.9%); the operating margin is 26.2% (peer median -1.9%).

Valuation It trades at 13.0× enterprise value to sales against a peer median of 4.1× (5th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 16.5 points below its cost of capital (18.1% WACC).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026ALEMBICLTD.NS 129Peer median 76
Six months, rebased to 100: Alembic against the median of its 20 peers (local-currency closes).

Alembic financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹2.13B₹2.40B₹2.22B₹1.57B₹1.27B
Revenue growth—+8%+41%+24%—
Gross profit₹941M₹1.02B₹1.03B₹734M₹496M
EBITDA₹698M₹919M₹942M₹571M₹405M
Net income₹3.55B₹3.17B₹3.11B₹2.69B₹1.91B
Free cash flown/a₹1.06B₹981M₹132M₹705M
Capital expendituren/a₹767M₹508M₹563M₹258M
Total debt₹0₹106M₹144M₹91.5M₹0

Quarterly statements and history in the cockpit →

Alembic competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%0%+20%301331000790688302RLMDINDSWFTLABINO368A300086005250SECARE60519941743005831720ALEMBICLTD.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Alembic is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×500×301331000790688302INDSWFTLABINO368A4174ALEMBICLTD.NSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alembic is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%+60%0%25%50%301331000790368A300086SECARE6030796051990021683005831720301509ALEMBICLTD.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Alembic is the large dot.

Alembic competitors and peer comparison

How Alembic compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alembic against its 20 peers (data as of 18 Nov 2026)
MeasureALEMBICLTD.NSPeer medianRank in peer set
1-month return+18.1%-9.7%3rd highest of 21
6-month return+25.1%-22.8%4th highest of 21
Distance from 52-week high-4.9%-38.0%highest of 21
Revenue growth (TTM)-4.7%+2.9%5th lowest of 19
Operating margin26.2%-1.9%2nd highest of 19
EV / Sales13.0×4.1×5th most expensive of 19
Growth the price implies (Req g, 7 yrs)44.3%6.1%2nd most demanding of 12
Growth delivered (Del g)+26.7%+2.3%2nd highest of 12
Hurdle (Req g minus delivered)+17.6 pp+4.9 pp4th most demanding of 12
ROIC minus cost of capital-16.5 pp-7.0 pp6th lowest of 18
EV / EBITDA39.6×9.6×most expensive of 6
Net debt / EBITDA-1.8×-0.6×3rd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Alembic ALEMBICLTD.NSIndia$309M+25%-5%26%13.0×44.3%+26.7%
Enwei Pharmaceutical 301331.SZChina$308M-20%-7%5%2.1×14.0%+7.3%
Chengdu Huasun Technology 000790.SZChina$312M-20%-36%-57%5.6×27.5%-6.4%
Hinova Pharmaceuticals 688302.SSChina$305M-35%+251%-195%17.1×n/an/a
Relmada Therapeutics RLMDUnited States$305M-60%n/an/an/an/an/a
Ind-Swift Laboratories INDSWFTLAB.NSIndia$314M+150%+66%9%3.4×n/an/a
Inovio Pharmaceuticals INOUnited States$317M+37%+64%-25,954%921.6×n/an/a
Kitazato 368A.TJapan$317M+7%+9%52%3.1×-16.8%+5.4%
Honz Pharmaceutical 300086.SZChina$299M-40%-23%-54%7.3×56.0%-12.8%
Atea Pharmaceuticals AVIRUnited States$320M-5%n/an/an/an/an/a
GC Corp. 005250.KSSouth Korea$321M-45%+2%3%1.1×n/an/a
Swedencare SECARE.STSweden$321M-24%+3%7%1.8×6.1%+62.1%
Zhejiang Shengda Bio-Pharm 603079.SSChina$297M-30%-3%7%2.3×4.6%-0.3%
Foresee Pharmaceuticals 6576.TWOTaiwan$322M-12%+6%-104%21.4×n/an/a
Hainan Huluwa Pharmaceutical 605199.SSChina$296M-21%-32%-58%4.8×1.4%-4.9%
OBI Pharma 4174.TWOTaiwan$295M+135%-2%-2,968%214.0×n/an/a
Beihai Gofar Chuanshan Biological 600538.SSChina$326M-39%+10%-8%6.2×n/an/a
Chongqing Hifuture Information Technology 002168.SZChina$326M-27%+2%-6%7.4×14.3%-14.0%
Shandong Sito Bio-technology 300583.SZChina$292M-30%+19%6%2.3×1.6%+2.3%
Standard Chemical & Pharmaceutical 1720.TWTaiwan$329M-1%+5%22%1.8×-11.5%+10.3%
Kingchem (Liaoning) Life Science 301509.SZChina$333M-28%+3%6%1.4×9.2%+6.5%

Questions

Which companies are Alembic's closest peers?
The cockpit's peer set: Enwei Pharmaceutical (301331.SZ), Chengdu Huasun Technology (000790.SZ), Hinova Pharmaceuticals (688302.SS), Relmada Therapeutics (RLMD), Ind-Swift Laboratories (INDSWFTLAB.NS), Inovio Pharmaceuticals (INO), Kitazato (368A.T), Honz Pharmaceutical (300086.SZ).
Is Alembic expensive compared with its peers?
On ev / sales it trades at 13.0× against a peer median of 4.1×, 5th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 44% a year for seven years (Req g). Recent delivered growth is +27%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Alembic stock performed?
Over six months to 18 Nov 2026 the shares returned +25.1% against -22.8% for the median peer; over one year +12.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.